Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.

Cell death & disease - 27 Feb 2026

Raivola Juuli, Rantanen Frida, Dini Alice, Piki Emilia, Barker Harlan, Multamäki Elina, Bentz Franziska, Sunkel Pia, Kiiski Aino-Maija, Paavolainen Lassi, Murumägi Astrid, Ungureanu Daniela

Abstract excerpt

Drug resistance remains a major challenge to durable responses in ovarian cancer, the fifth leading cause of cancer-related death among women. In this study, we developed long-term resistant (lt-res, several months) pre-clinical models of two drugs inducing mitotic arrest in TP53-mutated cells: adavosertib (ADA), an investigational WEE1 inhibitor targeting the DNA damage response and currently evaluated in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Checkpoints
Share to DNA Damage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ovarian Neoplasms

Share to Paclitaxel

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Pyrazoles

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 41748546
DOI: 10.1038/s41419-026-08501-x
PMCID: PMC13004963

Genes

ROR1
ADA
TP53
WEE1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.PMID 41748546Read ↗

Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment OptionsSemantic proximity Read ↗

Systems approach to rational combination therapy: PARP inhibitorsSemantic proximity Read ↗

Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancerSemantic proximity Read ↗

AKT1 interacts with DHX9 to Mitigate R Loop–Induced Replication Stress in Ovarian CancerSemantic proximity Read ↗

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.Semantic proximity Read ↗

Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.Semantic proximity Read ↗

mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAsSemantic proximity Read ↗

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress.Semantic proximity Read ↗

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.Semantic proximity Read ↗

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Semantic proximity Read ↗

Dual actionability of BMI1 activation and mitotic vulnerability defines adaptive Osimertinib resistance in EGFR-mutant NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.